Category: therapeutics

Mesenchymal stem cells isolated from human umbilical cord (hMSCs) are modified for the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease).

Category(s):
Subcategory(s):

The technology presents a novel structural modification of an existing first generation Grp94 selective inhibitor to generate a second generation Grp94-specific scaffold which has greater affinity and selectivity compared to existing inhibitors and prevents unfavorable binding of other Hsp90 isoforms.

Category(s):

Unique chemical derivatives invented by University of Kansas (KU) researchers that could be used to detect inhibitors of cellular efflux transporters and other agents. 

Category(s):

Novel ligands designed to activate mu opioid receptors and provide analgesic effects without opioid-related side effects, providing specific insight into the cellular impact of opioid receptor-based activation as related to pain medications.  These ligands could be used as a tool to negate drug tolerance and dependence as well as other adverse side effects.

Photo-mediated Ultrasound Therapy (PUT) is a non-pharmacological, highly targeted, non-invasive treatment which selectively disrupts the microvasculature (arteries or veins independently) without catheterization/injection or damage to the surrounding tissue.

Category(s):
Subcategory(s):

The invention relates to protecting against Salmonella-type pathogens and more particularly, compositions and methods for immunizing against infection by typhoidal and non-typhoidal Salmonella serovars.

Category(s):

This invention describes the first selective inhibitor of heat shock protein 90 kDa beta (Hsp90β). The invented inhibitor selectively binds to the N-terminus of Hsp90β and may be developed for the treatment of cancers. The inhibitor was developed based on the sequence alignment of the N-terminal ATP-binding domains of Hsp90α and Hsp90β complexed with a non-selective Hsp90 inhibitor, which revealed Hsp90β-specific residues that were key to exploit the selectivity of the new inhibitor. 

Category(s):
Subcategory(s):

Structural modification of a non-selective aminocyclohexanol-based heat shock protein 90 KDa (Hsp90) inhibitor led to a highly selective inhibitor of glucose regulated protein 94 kDa (Grp94). The new Grp94-selective inhibitor can be used to develop an effective therapy for the treatment of metastatic cancer and/or primary open angle glaucoma (POAG).

Category(s):
Subcategory(s):

Use of a genetic dereplication strategy eliminates major known SM biosynthetic pathways in Aspergillus nidulans, reducing the complexity of SM profiles and activating an abundance of silent SM gene clusters to enable identification of a new pool of fungal products for drug discovery.

Subcategory(s):

Selective heat shock protein 90 (Hsp90) and glucose regulated protein 94 (Grp94) inhibitors that can be used to develop an effective therapy for treating primary open angle glaucoma (POAG).

Category(s):
Subcategory(s):

Pages


Events
KU Today